[Antiphospholipid antibodies and cancer]

Area of Science:

• Immunology
• Hematology
• Oncology

Context:

• Antiphospholipid antibodies (APLA) are a diverse group targeting phospholipid-binding proteins.
• Laboratory diagnosis of APLA is complicated by heterogeneity and lack of standardization.
• Antiphospholipid syndrome (APS) involves recurrent thrombosis linked to positive APLA tests.

Purpose:

• To elucidate the complexities of antiphospholipid antibody diagnosis and their association with thrombotic events.
• To highlight the link between antiphospholipid syndrome and underlying conditions, particularly malignancy.

Summary:

• APLA are antibodies recognizing combinations of phospholipids and binding proteins.
• APS is an immune-mediated thrombophilia characterized by recurrent thrombosis.
• APLA diagnosis is challenging due to antibody heterogeneity and test standardization issues.
• APLA-associated thrombosis can be an early sign of malignancy.
• Malignancy elevates thrombosis risk in patients with APLA.
• Catastrophic APS is a rare, life-threatening variant involving multiple organ failure.

Impact:

• Improved understanding of APLA and APS diagnostic challenges.
• Enhanced awareness of the association between APLA, thrombosis, and malignancy.
• Potential for earlier detection of malignancy in APS patients.
• Informing clinical practice for managing thrombotic risk in APS.